CD36 and breast cancer: Furthermore, the Wnt pathway appears to modulate the CD36 level mainly in therapy-resistant HER2 + BC cell lines characterized by decreased baseline expression of CD36 (HCC1954/EFM192A vs. MDAMB361/HCC1569), where CD36 expression is likely restricted to the CSC population, in which it leads to increased MS formation.